EVOLVE-105

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameEVOLVE-105
Drug Alias NameEVOLVE-105
ClassificationBiologics > T cell engagers
Mechanisms of ActionAnti-CD20CD3 T-cell engagersAnti-CD2
TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3T-cell surface antigen CD2
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEvolveImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEvolveImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A